Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)

v3.25.0.1
Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
shares in Thousands
 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Class of Stock [Line Items]    
Shares excluded from the calculation of diluted loss per share 12,837 5,378
Employee Stock Option    
Class of Stock [Line Items]    
Shares excluded from the calculation of diluted loss per share 1,058 36
Restricted Stock Units    
Class of Stock [Line Items]    
Shares excluded from the calculation of diluted loss per share 12 3
Warrants    
Class of Stock [Line Items]    
Shares excluded from the calculation of diluted loss per share 11,521 5,339
AstralBio Exclusive License Agreement    
Class of Stock [Line Items]    
Shares excluded from the calculation of diluted loss per share 246